3D-Culture, Organoids & Tox Screening Europe (Rotterdam, Netherlands - June 13-14, 2019)

  • ID: 4751485
  • Conference
  • Location: Rotterdam, Netherlands
  • 2 Days
  • Select Biosciences
  • Conference Dates: June 13-14, 2019
1 of 5

3D-Culture, Organoids & Tox Screening Europe 2019 brings together researchers from around the world focusing on the emerging technologies and applications of 3D-culture and organoids, especially as they are impacting drug discovery, toxicity screening and drug development processes.

Hear from and network with researchers who are currently screening for efficacy and toxicity using iPS cell lines (and cells derived thereof), and those responsible for developing the techniques and technologies in the organoids field. There will also be discussions on industry and regulatory developments that are shaping the future of 3D-culture and technologies for studying organoids in cancer research and beyond.

Topics to be covered include 3D-cell based screening methods, high content screening and data management, the use of model organisms and novel approaches for phenotypic screening.

Key Opinion Leaders from around the World are Participating at this Conference allowing Maximal Information Exchange and Unparalleled Networking Opportunities.

Benefits of Attending:

  • The most up-to-date science is presented in the given fields of research represented at the conference
  • Conference speakers are experts in their respective fields and many key opinion leaders (KOLs) participating and speaking at these events
  • Extensive networking opportunities with academics and industry participants - networking in a professional business environment conducive to partnering, collaborations and business development activities
  • Excellent venue located right across from Rotterdam Centraal Station with extensive fast connections across Europe, fast Thalys trainstop to Antwerp, Brussels and Paris, and a fast direct train to Amsterdam Schiphol Airport for flight connections around the world
  • Breakfasts, lunches and networking cocktail reception for a relaxed business atmosphere conducive to excellent networking
  • Right across from Marriott Rotterdam with conference pricing for conference attendees allows delegates easy access to the conference and after-hours networking opportunities with colleagues
  • Manageable conference sizes composed of several hundred delegates facilitates.

*Please Note: Academic pricing provided on enquiry.

READ MORE
Note: Product cover images may vary from those shown
2 of 5

Day 1 - Thursday, 13 June 2019

08:00

Conference Registration, Materials Pick-Up, Morning Coffee and Pastries

08:50

Terry Riss - Conference Chair

  • Chairman's Welcome and Introduction to the Conference
  • Terry Riss, Global Strategic Marketing Manager Cell Health, Promega Corporation, United States of America

Session Title: Conference Opening Session

09:00

Gary Gintant - Keynote Presentation

  • In vitro Safety Assays with Human Derived Cardiomyocytes…. .…Bridging the Translational Gap?
  • Gary Gintant, Senior Research Fellow, Abbvie, United States of America

Clever biological and engineering endeavors are providing numerous novel opportunities to address cardiac safety issues of drug candidates with the intent of bridging the "translational gap" between preclinical and clinical studies. These efforts involve both "generalized" and patient-specific cardiac preparations. The utility of such studies depend not only on the evolving preparations, but also on the appropriate questions and interpretations, both representing challenges for future efforts.

09:45

David Hay - Keynote Presentation

  • Generating Human Liver Spheres From Pluripotent Stem Cells and Their Application
  • David Hay, Chair of Tissue Engineering, MRC Centre for Regenerative Medicine, University of Edinburgh, United Kingdom

Liver disease is an escalating global health issue. While liver transplantation is an effective mode of therapy, there are a shortage of donor organs. Therefore, developing renewable sources of human liver tissue is important for the clinic. Pluripotent stem cell-derived liver tissue represents a potential alternative to cadaver derived hepatocytes and whole organ transplant. At present, two-dimensional differentiation procedures deliver tissue that is hepatocyte like, but lacks certain functions and long-term stability. Efforts to overcome these limiting factors have focussed on building three-dimensional (3D) cellular aggregates. Although enabling for the field, their widespread application has been limited due to cost and overreliance on undefined biological components. Our studies focused on the development of self assembled 3D liver tissue under defined conditions. In vitro generated 3D tissues exhibited stable phenotype, providing an attractive resource for the clinic and long-term in vitro modelling studies. Our most recent tissue engineering advances will be discussed at the meeting.

10:30

Morning Coffee Break and Networking in the Exhibit Hall

11:15

James Hickman - Keynote Presentation

  • Title to be Confirmed.
  • James Hickman, Professor, Nanoscience Technology, Chemistry, Biomolecular Science and Electrical Engineering, University of Central Florida; Chief Scientist, Hesperos, United States of America

12:00

  • InSphero AGGoing 3D All the Way: 3D Microtissues in 384-well Plates and Modular Organ-on-a-Chip Solutions for Patient-Centric Drug Discovery
  • Jan Lichtenberg, CEO & Co-Founder, InSphero AG

Scaffold-free 3D microtissues have evolved into the most widely used technology for highly predictive and most scalable cell-based assays in drug safety and discovery. While they provide a faithful in-vitro approximation of the in-vivo tissue microenvironment, they were not amenable for modeling microphysiological features up to now. Focusing on advantages and challenges in daily industry use, we’ll describe two case studies illustrating how a 3D microtissue can be used as a predictive surrogate for drug discovery. One study investigates a complex co-culture system recapitulating the hallmarks of nonalcoholic steatohepatitis (NASH) in a screening-compatible format. Consisting of primary human hepatocytes, NPCs and stellate cells, these 3D microtissues can be elastically driven into and out of specific disease states. As second application, we will describe the use of reconstituted, 3D primary human pancreatic islets for discovery of anti-diabetic drugs. Finally, we present a new multi-organ-on-a-chip system featuring microfluidic channels and chambers that were specifically engineered for culturing 3D microtissues and organoids under physiological flow conditions. The platform complies with the SBS plate standard and is made of polystyrene to prevent unwanted compound absorption. It allows for an automated and on-demand interconnection of up to 10 microtissues per channel in a highly flexible fashion. Enabling an automated removal and re-insertion of 3D microtissues from and into the device, this platform finally ads deep endpoints such as next-gen sequencing, lipidomics, FACS to the analytical toolbox for organ-on-a-chip applications. Summarizing, we will focus on the major challenges encountered when implementing human, primary cell based 3D and organ-chip assays - and our suggestions on how to address them in an industry-wide effort.

12:30

Networking Lunch in the Exhibit Hall and Poster Viewing

  • Emerging Themes in Organoids and Organs-on-Chips: An Introduction
  • Session Chair: Paul Vulto, Managing Director, MIMETAS, Netherlands

Session Title: Organoids and 3D-Culture - Technologies and Applications

14:00

  • Phenotypic Screening in 3D Culture Including ECM: Advantages and Challenges
  • Nathalie Maubon, CEO/CSO, HCS Pharma, France
  • Grégory Maubon, Digital Coordinator, HCS Pharma, France

Cellular assays in 3D culture have shown many advantages to better mimic the in vivo situation. 3D technologies for phenotypic screening have become simpler and more accessible, such as the use of Ultra Low Attachment (ULA) plates. However, we can now go even further using 3D technologies which allow us to reproduce the micro-environment of healthy or pathological organs of interest. During this talk, we will show how the cellular microenvironment impacts the proliferation and/or differentiation of cells. A few examples from the fields of oncology, CNS and metabolic disease will be presented. High-Content Screening (HCS) devices, such as our ImageXpress® Micro Confocal system, are now fast enough and sensitive enough to allow image acquisition in 3D cellular models. Nevertheless, to go further, perceptions and processes need to be changed. We will discuss cutting-edge new technologies, including virtual and augmented realities, deep learning and machine learning, and explain how these new technologies can be of benefit to phenotypic screening.

14:30

  • Factors to Consider When Choosing a 3D Cell Culture Model System
  • Terry Riss, Global Strategic Marketing Manager Cell Health, Promega Corporation, United States of America

There continues to be a rapid expansion in the use of 3D cell culture model systems because they more closely represent the in vivo situation compared to culturing cells as a monolayer attached to plastic. There are many approaches classified as 3D culture models ranging from individual scaffold-free spheroids to human-on-a-chip. Researchers soon become aware this spectrum of models have vastly different requirements and there is no "one size fits all" approach. Selecting a 3D culture model that is "fit for purpose" involves several decisions and often results in a compromise between sample throughput and culture model complexity or cost. We will describe an overview of factors to consider when designing or selecting an appropriate 3D culture model addressing: sample size, scaffolds, culture medium, choice of assay methods, and reproducibility. Attendees should acquire an increased awareness of the range of available approaches and be able to use the information to design an appropriate 3D culture model.

15:00

  • BrainSpheres to Study Developmental Neurotoxicity
  • David Pamies, Researcher, University of Lausanne, Switzerland

Developmental neurotoxicity is of high concern due to different reasons: 1) no routine testing for DNT is carried out in the U.S., in the EU, or elsewhere, as DNT testing is not required by law unless triggered by neurotoxic or endocrine effects in adult rodents, 2) DNT guidelines are expensive and time-consuming, 3) human brain complexity may not be completely tested by animal testing, and 4) brain defects can be difficult to detect. Experts in the field have suggested an in vitro testing battery to cover brain development key events (such as neural stem cell proliferation and differentiation, migration, neurite outgrowth, synaptogenesis, network formation, myelination, and apoptosis). Also, the use of more human-relevant models, using 3D organotypic iPSC derived systems, have been suggested as an alternative to classical in vitro models. Here we present a 3D brain human-derived iPSC model to study developmental neurotoxicity and different applications of the model.

15:30

Afternoon Coffee Break and Networking in the Exhibit Hall

16:00

  • High Content Screening of Organoid Cultures to Visualize and Quantify Intestinal Toxicity
  • Bram Herpers, COO, OcellO B V, Netherlands

Establishing organoids from human material enables development of 3D cell culture models for the intestinal epithelium to investigate physiological and toxicological mechanisms. At OcellO we combine a high throughput 3D human intestinal organoid culture platform with high content phenotype-based analysis to visualize and quantify the effects of compounds and treatment conditions on the epithelial integrity, injury and inflammation in a diverse (healthy and diseased) patient-derived organoid population.

16:30

  • 3D Microtumor-based Combinatorial Drug Discovery
  • Jens Kelm, CEO and Co-Founder, PreComb Therapeutics AG, Switzerland

3D tissue culture technologies for drug discovery are becoming of age. However, new 3D technologies and models are primarily used to exchange existing models to improve individual aspects in the developmental process. However, 3D models do not only reflect tissue and organ disease biology better than 2D models they allow to create novel assays to build completely new drug development processes. To take full advantage of 3D we present a 3D-based discovery processes to develop novel drug combinations.

17:00

Paul Vulto - Keynote Presentation

  • Title to be Confirmed.
  • Paul Vulto, Managing Director, MIMETAS, Netherlands

17:45

Networking Reception with Beer and Wine - Meet Colleagues and Network with New Acquaintances

18:45

Close of Day 1 of the Conference

Day 2 - Friday, 14 June 2019

08:00

Morning Coffee, Pastries and Networking in the Exhibit Hall

Session Title: Tox Screening and Enabling Technologies

09:00

Roger Kamm - Keynote Presentation

  • 3D Microphysiological Models of Neurological Function and Disease and Their Application to Drug Screening
  • Roger Kamm, Cecil and Ida Green Distinguished Professor of Biological and Mechanical Engineering, Massachusetts Institute of Technology (MIT), United States of America

The capability to produce in vitro models of normal physiological function and disease is rapidly expanding, and it is now becoming clear that these microphysiological systems (MPS) will soon find their place in the multi-step process of identifying and vali-dating new drugs, and testing for their potentially toxic side-effects. In order to gain acceptance by the pharma and biotech industries, however, these systems will need to be further developed, validated, and methods developed to fabricate them at high throughput and consistency. In this presentation, we focus on systems being developed to model neurological function, disease, and the process of transport of drugs across the tight blood-brain barrier (BBB) to treat neurological disorders and cancer. These MPS are each derived entirely from human cells, produced in microfluidic platforms of different design, and include models of the BBB, Alzheimer’s Disease, and amyotrophic lateral sclerosis (ALS).

09:45

  • Quantitative Assessment of Tissue Chip Technologies
  • Murat Cirit, Director at Translational Center of Tissue Chip Technologies, Massachusetts Institute of Technology (MIT), United States of America

A large percentage of drug candidates fail at the clinical trial stage due to a lack of efficacy and unacceptable toxicity, primarily because the in vitro cell culture models and in vivo animal models commonly used in preclinical studies provide limited information about how a drug will affect human physiology. The need for more physiologically relevant in vitro systems for preclinical efficacy and toxicity testing has led to a major effort to develop "Microphysiological Systems (MPS)", aka tissue chips (TC), based on engineered human tissue constructs. Translational Center of Tissue Translational Center of Tissue Chip Technologies (TC2T) has been established to bridge between academic research and development and industrial application of MPS technologies via providing unbiased testing and validation of MPS technologies. We believe that the full impact of MPS technologies will be realized only when robust approaches for in vitro-in vivo (MPS-to-human) translation are developed and utilized. Therefore, TC2T takes a holistic approach-based on quantitative systems pharmacology (QSP)- to achieve quantitative characterization of these complex systems and translation of experimental insights to clinical outcomes.

10:15

Morning Coffee Break and Networking

11:00

  • Accurate Prediction of Organ-Specific Toxicities
  • Daniele Zink, Principal Research Scientist and Team Leader, Institute of Bioengineering and Nanotechology, Agency for Science Technology and Research (A*STAR), Singapore

Predicting toxicity to internal organs with alternative methods is currently a major challenge. We have developed the first methods that predict nephrotoxicity in humans with high accuracy. These methods include a high-throughput platform, which combines high-throughput screening (HTS) with phenotypic profiling and machine learning. With this technology toxicity to renal proximal tubular cells (PTC) could be predicted with 82% or 89% test balanced accuracy, depending on whether primary human PTC or a human PTC line were used. Based on the same technology we have developed a HTS platform for the prediction of hepatotoxicity in humans. This HTS platform has been validated with ~90 compounds that were separated into training and test sets, and both test sensitivity and specificity are in the range of 80%. In addition, we have developed a HTS platform for the prediction of vascular toxicity. Our predictive HTS methods are currently combined with our predictive approaches based on human induced pluripotent stem cells.
 
While the HTS platforms are robust, suitable for rapid compound screening and produce binary (yes/no) results with respect to toxicity prediction, we develop complementary microphysiological systems (MPS) for repeated dose testing. Results obtained with a kidney-specific MPS show a high correlation between IC50 values obtained in vitro and the lowest toxic doses in humans. It is expected that respective MPS can greatly facilitate in vitro to in vivo extrapolations (IVIVE). Current difficulties in this area are one of the major obstacles that prevent applications of in vitro methods in risk assessment.

11:30

  • Title to be Confirmed.
  • Robert Halliwell, Professor of Neuroscience and Clinical Pharmacology, University of The Pacific, United States of America

12:00

Peter Ertl - Keynote Presentation

  • Formation, Cultivation and Analysis of 3D Microtissues using a Microfluidic Multicellular Spheroid Array
  • Peter Ertl, Professor of Lab-on-a-Chip Systems, Vienna University of Technology, Austria

A long-standing trend in pharmaceutical development, toxicology and biomedicine has been the establishment of complex in vitro 3D cell cultures whose structures and function resemble human tissues. To meet the growing need to improve the predictive power of toxicological, pharmaceutical and preclinical studies, the multicellular spheroid array builds on the advancement of novel organ-on-a-chip technology that establishes, cultivates and supports a wide variety of multicellular spheroids (3D cell aggregates). This system thus closes an important technological gap, enabling rapid and easy production of spheroids of defined size and cell types.

12:45

Networking Lunch, Exhibit and Poster Viewing

13:45

Poster Awards

14:00

  • Prediction of Gastrointestinal Toxicity and Drug Absorption Using the Reconstructed 3D Model of Human Small Intestine Epithelium (EpiIntestinal)
  • Jan Markus, Production Manager/Senior Scientist, MatTek IVLSL, Slovak Republic

Small intestine is an important entry gateway for many nutrients, drugs and other substances. About 90% of orally administered drug absorption occurs in the small intestine. Thereby there is a need of good and reliable in vitro model capable to predict drug toxicity and absorption/metabolism patterns that would replace intestine models relying predominantly on the use of cell lines generated from the colon or kidney.

The reconstructed 3D human small intestine model - EpiIntestinal mimics morphology and cell-type composition of normal human small intestine. It is polarized, allows studying bidirectional drug penetration through intestinal wall and expresses proteins involved in active drug transport and metabolism at physiological level. This allows modelling of complex drug absorption profiles, including the permeation, metabolism, drug-drug interaction and adverse effects of drugs on epithelium. Our results revealed that EpiIntestinal mimics the in vivo drug absorption profile much closer than the cancer cell line-based model. EpiIntestinal was also shown to predict toxicity with much higher specificity and sensitivity than the animal model. All in all, this model represents a promising tool to model complex processes occurring in small intestine.

14:30

  • High-Throughput Microfluidic Platform for Drug Screening of Vascularized 3D Tissues
  • Sara Previdi, Scientist, University Medical Center Leiden, Netherlands

3D tissues such as spheroids or organoids derived from human pluripotent stem cells (PSCs) represent a new type of three-dimensional in vitro model for understanding organ development, disease mechanism and drug testing. Despite the success in generating 3D cultures resembling different tissue types (brain, heart, intestine, liver, lung and kidney), these mini-organs show limited growth potential and an immature phenotype due to lack of vascularization. Several groups have attempted to improve vascularization of organoids by transplanting them into a host (i.e. mouse, chick). However, the low predictivity of animal models, boost the development of in vitro alternative strategies. In this regard, microfluidic techniques are increasingly recognized as important toolbox able to add physiologically relevant cues to traditional cell culture models. We recently described the use of the OrganoPlate® for generating 3D perusable angiogenic vessels. Here, we present the use of a high-throughput 'grafting' platform which allows vessels co-culture with 3D tissue aggregates and tissue vascularization. One unit of the Mimetas OrganoPlate® Graft is made of two microfluidic channels in which endothelial cells can be patterned against ECM through the use of the PhaseGuide® technology. Gradient of pro-angiogenic factors (VEGF, PMA, S1P and FGF-b) allows the formation of a perfused vascular bed on top of which tissue fragments (i.e. organoids or spheroids) can be added to enable vascularization. Tissue dependent vessels remodeling and stabilization can be monitored overtime by real time imaging and barrier integrity. When liver spheroids are used, vessels became leaktight to dextran 150 kDa after 14 days of co-culture. Moreover, expression of CD31+ cells around and in within the spheroids proves that endothelial cells migration and tissue envelopment occurred during co-culture. The high number of units (up to 64 chips in 384 well format) enables functionality studies and compound screening in a robust and automated way. We propose the use of the OrganoPlate® Graft as a vessels grafting platform for multiple 3D tissues allowing drug screening and disease modeling in a more physiological environment.

15:00

  • Human Induced Pluripotent Stem (iPS) Cells in Glaucoma Modeling with an Automated Platform and 3D Retinal Organoids
  • Maciej Daniszewski, Researcher, University of Melbourne, Australia

Glaucoma is a disease characterized by slow degeneration of retinal ganglion cells (RGCs) what leads to irreversible vision loss and may ultimately result in blindness. It is estimated that approximately 80 million people will be affected by the disease in 2020, and with aging populations, this number will only continue to grow, thus generating a significant financial burden on the healthcare system.

15:30

Afternoon Coffee Break and Networking

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

Conference Chair

Terry Riss
Global Strategic Marketing Manager Cell Health, Promega Corporation

Keynote Speakers

Roger Kamm
Cecil and Ida Green Distinguished Professor of Biological and Mechanical Engineering, Massachusetts Institute of Technology (MIT)

James Hickman
Professor, Nanoscience Technology, Chemistry, Biomolecular Science and Electrical Engineering, University of Central Florida; Chief Scientist, Hesperos

Peter Ertl
Professor of Lab-on-a-Chip Systems, Vienna University of Technology

Paul Vulto
Managing Director, MIMETAS

Gary Gintant
Senior Research Fellow, Abbvie

David Hay
Chair of Tissue Engineering, MRC Centre for Regenerative Medicine, University of Edinburgh

Speakers

Murat Cirit
Director at Translational Center of Tissue Chip Technologies, Massachusetts Institute of Technology (MIT)

Maciej Daniszewski
Researcher, University of Melbourne

Robert Halliwell
Professor of Neuroscience and Clinical Pharmacology, University of The Pacific

Bram Herpers
COO, OcellO B V

Jens Kelm
CEO and Co-Founder, PreComb Therapeutics AG

Jan Lichtenberg
CEO & Co-Founder, InSphero AG

Jan Markus
Production Manager/Senior Scientist, MatTek IVLSL

Grégory Maubon
Digital Coordinator, HCS Pharma

Nathalie Maubon
CEO/CSO, HCS Pharma

David Pamies
Researcher, University of Lausanne

Sara Previdi
Scientist, University Medical Center Leiden

Daniele Zink
Principal Research Scientist and Team Leader, Institute of Bioengineering and Nanotechology, Agency for Science Technology and Research (A*STAR)

Note: Product cover images may vary from those shown
5 of 5
  • Academic researchers - both junior and established investigators
  • Students and postdoctoral fellows are encouraged to submit poster abstracts and present their research at the conference in poster format - allows research exposure to fellow researchers around the world and collaborations development
  • Industry participants - researchers from industry as well as corporate and business development attendees from companies - excellent opportunity to network at the events and to build partnerships, networks, collaborations
  • Vendors offering technologies, tools, products and services - conferences offer good opportunities to reach out to potential customers.
Note: Product cover images may vary from those shown
6 of 5

ADDRESS

Rotterdam Marriott
Weena 686, 3012 CN
3012 CN
Rotterdam
Netherlands


DETAILS


Set on the first 15 floors of a modern glass-and-steel high-rise, this posh hotel lies opposite Rotterdam Centraal Station, 1.6 km from the Cube houses and 2.1 km from Diergaarde Blijdorp zoo.

The sophisticated rooms and suites offer free Wi-Fi, flat-screen TVs, minibars, and tea and coffeemakers, plus marble bathrooms with showers and tubs. Upgraded rooms add skyline views, espresso machines and/or access to a private lounge, while suites feature living areas and include breakfast. Room service is available 24/7.

There's a stylish brasserie, a chic cocktail lounge and a lobby cafe. Other amenities include 8 meeting rooms and a 24-hour gym.

Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4751485
Adroll
adroll